Trials / No Longer Available
No Longer AvailableNCT02755987
Expanded Access to ANG1005 for Individual Patients
Expanded Access to ANG1005 for an Individual Patient With Recurrent WHO Grade III Anaplastic Astrocytoma; Expanded Access to ANG1005 for an Individual Patient With Recurrent WHO Grade III Anaplastic Oligodendroglioma; Expanded Access to ANG1005 for an Individual Breast Cancer Patient With Recurrent Brain Metastases and Leptomeningeal Carcinomatosis.
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Angiochem Inc · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This is an expanded access study with ANG1005 treatment for two individual patients from Protocol ANG1005-CLN-03 with WHO Grade III Anaplastic Astrocytoma and WHO Grade III Anaplastic Oligodendroglioma and one individual patient from Protocol ANG1005-CLN-04 with Recurrent Brain Metastases and Leptomeningeal Carcinomatosis.
Conditions
- Anaplastic Astrocytoma
- Anaplastic Oligodendroglioma
- Breast Cancer With Recurrent Brain Metastases
- Leptomeningeal Carcinomatosis
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ANG1005 |
Timeline
- First posted
- 2016-04-29
- Last updated
- 2016-06-07
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02755987. Inclusion in this directory is not an endorsement.